|Bid||133.16 x 200|
|Ask||133.38 x 100|
|Day's range||130.07 - 133.39|
|52-week range||95.08 - 149.31|
|PE ratio (TTM)||324.59|
|Earnings date||21 Feb 2018 - 26 Feb 2018|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||146.50|
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered assets and its OmniAb® and Captisol® technology platforms.
Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.
Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
Biotech stocks have been big winners this year. But since they can lose 50% in a single day, readers have asked if there is a "safer" way to invest. Bruce Pile tells us about Ligand Pharmaceuticals and Xoma Corp., two biotechs that do not bet the whole company on a single drug candidate.
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Intrexon (XON) reported narrower-than-expected loss but revenues missed estimates in the third quarter of 2017. The company remains focused on the development of its pipeline candidates.
The San Diego-based company said it had profit of 36 cents per share. Earnings, adjusted for one-time gains and costs, came to 69 cents per share. The drugmaker posted revenue of $33.4 million in the period, ...